This fixed-dose combination is used for the management of Type 2 Diabetes Mellitus when diet and exercise alone are insufficient. It works through three complementary mechanisms: Metformin ER reduces hepatic glucose production and improves insulin sensitivity, Glimepiride stimulates insulin secretion from pancreatic beta cells, and Dapagliflozin enhances urinary glucose excretion via the kidneys. Together, they provide effective and sustained glycaemic control.
